天境生物(纳斯达克：IMAB)股价差距高达12.34美元

#天境生物(纳斯达克：IMAB)股价差距高达12.34美元| 来源: 网络整理| 查看: 265

I-Mab (NASDAQ:IMAB – Get Rating) shares gapped up prior to trading on Wednesday . The stock had previously closed at $12.34, but opened at $12.64. I-Mab shares last traded at $12.05, with a volume of 5,881 shares traded.

A number of research firms have recently commented on IMAB. Needham & Company LLC dropped their price objective on I-Mab from $85.00 to $72.00 and set a "buy" rating on the stock in a research note on Tuesday, May 31st. Piper Sandler dropped their price objective on I-Mab from $80.00 to $35.00 in a research note on Friday, May 27th. Finally, HC Wainwright dropped their price objective on I-Mab from $80.00 to $70.00 and set a "buy" rating on the stock in a research note on Tuesday, May 31st. Five analysts have rated the stock with a buy rating, According to MarketBeat.com, the company has an average rating of "Buy" and an average target price of $78.50.

Get I-Mab alerts:

The business has a 50-day moving average price of $10.98 and a 200-day moving average price of $20.31.

Several institutional investors have recently made changes to their positions in the company. Bank of America Corp DE raised its position in shares of I-Mab by 14.1% during the first quarter. Bank of America Corp DE now owns 875,229 shares of the company's stock worth $14,213,000 after purchasing an additional 107,996 shares during the period. The Manufacturers Life Insurance Company raised its position in shares of I-Mab by 0.3% during the first quarter. The Manufacturers Life Insurance Company now owns 479,503 shares of the company's stock worth $7,787,000 after purchasing an additional 1,500 shares during the period. Goldman Sachs Group Inc. raised its position in shares of I-Mab by 98.3% during the first quarter. Goldman Sachs Group Inc. now owns 726,692 shares of the company's stock worth $11,801,000 after purchasing an additional 360,273 shares during the period. Wellington Management Group LLP acquired a new stake in shares of I-Mab during the first quarter worth $548,000. Finally, State Street Corp raised its position in shares of I-Mab by 20.5% during the first quarter. State Street Corp now owns 751,254 shares of the company's stock worth $12,200,000 after purchasing an additional 127,890 shares during the period. 96.17% of the stock is currently owned by institutional investors.

I-Mab Company Profile (NASDAQ:IMAB)

I-Mab, a clinical stage biopharmaceutical company, discovers, develops, and commercializes biologics to treat cancer and autoimmune disorders. It is developing Felzartamab, a CD38 antibody that is in Phase 1b/2a for patients with membranous nephropathy; Eftansomatropin alfa, a long-acting human growth hormone, which has completed Phase 3 clinical trials to treat pediatric growth hormone deficiency; TJ107, a recombinant human IL-7, which is in Phase 2 for cancer treatment-related lymphopenia and cancer immunotherapy; and Lemzoparlimab, a CD47 monoclonal antibody that has completed Phase 2 clinical trial.